|Day's Range||32.36 - 32.56|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||22.70|
|Dividend & Yield||1.03 (3.14%)|
|1y Target Est||N/A|
Roche (RHHBY) announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera/Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers.
The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk
Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . Some analysts called Monday's data release convincing, with Jefferies saying it underpinned its $5 billion peak sales estimate for the medicine.